Revenue Decline – Talk Bio

Actionable Insights Powered by AI

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

1 week ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

WuXi AppTec Faces Revenue Decline Amid Looming BIOSECURE Act Threat

12 months ago talkbio0Tagged AppTec, BIOSECURE, Biotechnology, Relations, Revenue Decline, WuXi

WuXi AppTec, BIOSECURE Act, Revenue Decline, Biotechnology, US-China Relations